Table 1.
Symbol | Definition | FDR | Fold change |
---|---|---|---|
(a) In vivo dataa | |||
VEGFA | Vascular endothelial growth factor A | 0.13 | 2.44 |
SERPINB5 | Serpin peptidase inhibitor, clade B (ovalbumin), member 5 | 0.13 | 1.78 |
EDN1 | Endothelin | 0.13 | 0.44 |
PTX3 | Pentraxin 3, long | 0.13 | 0.54 |
AREG | Amphiregulin | 0.24 | 1.53 |
FGF1 | Fibroblast growth factor 1 (acidic) | 0.24 | 0.67 |
(b) In vitro datab | |||
PLG | Plasminogen | 0.001 | 124.82 |
SERPINF1 | Serpin peptidase inhibitor, clade F (alpha‐2 antiplasmin, pigment epithelium‐derived factor), member 1 | 0.001 | 27.32 |
AREG | Amphiregulin | 0.013 | 6.74 |
ARTN | Artemin | 0.013 | 4.98 |
FGF7 | Fibroblast growth factor 7 | 0.013 | 5.85 |
LEP | Leptin | 0.013 | 5.52 |
THBS2 | Thrombospondin 2 | 0.013 | 5.32 |
CSF2 | Colony stimulating factor 2 (granulocyte‐macrophage) | 0.017 | 3.65 |
ANGPT1 | Angiopoietin 1 | 0.017 | 2.84 |
EGF | Epidermal growth factor | 0.017 | 5.52 |
FGF4 | Fibroblast growth factor 4 | 0.017 | 4.88 |
IL1B | Interleukin 1, beta | 0.017 | 4.00 |
VEGFA | vascular endothelial growth factor A | 0.017 | 7.47 |
ANGPT2 | Angiopoietin 2 | 0.02 | 2.64 |
FGF2 | Fibroblast growth factor 2 (basic) | 0.024 | 3.74 |
ADAMTS1 | ADAM metallopeptidase with thrombospondin type 1 motif, 1 | 0.025 | 42.03 |
ANG | Angiogenin, ribonuclease, RNase A family, 5 | 0.031 | 3.84 |
PRL | Prolactin | 0.032 | 2.95 |
PTX3 | Pentraxin 3, long | 0.032 | 2.62 |
CCL3 | Chemokine (C‐C motif) ligand 3 | 0.034 | 2.72 |
PROK1 | Prokineticin 1 | 0.034 | 2.41 |
CCL2 | Chemokine (C‐C motif) ligand 2 | 0.036 | 2.60 |
HGF | Hepatocyte growth factor (hepapoietin A; scatter factor) | 0.037 | 1.92 |
TYMP | Thymidine phosphorylase | 0.040 | 3.45 |
CXCL8 | Chemokine (C‐X‐C motif) ligand 8 | 0.045 | 4.96 |
FGF1 | Fibroblast growth factor 1 (acidic) | 0.049 | 1.72 |
Factors in bold were investigated in further detailed studies.
Abbreviation: FDR, false discovery rate.
Using a Proteome profiler angiogenesis array covering 56 key angiogenic factors, 3 overexpressed proteins and 3 underexpressed (defined as the change of expression by at least 50%) were detected in tumour xenografts of mice treated orally with A platensis extract for 2 wk (0.5 g/kg once daily).
Using the same array, 26 differentially expressed proteins (defined as FDR < 0.05) as a result of 2‐d exposure of human PA‐TU‐8902 pancreatic cancer cells to the A platensis extract (0.6 g/L) were detected.